Harbour BioMed
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
Top Stages
2 past transactions
HBM Alpha Therapeutics
Seed Round in 2023
A biotechnology company developing antibody therapeutics targeting rare genetic diseases such as congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its platform aims to treat other endocrinological diseases associated with hypothalamic-pituitary-adrenal axis dysregulation.
Harbour Antibodies
Acquisition in 2016
Founded in 2006, Harbour Antibodies specializes in producing therapeutic antibodies and VH domains. It offers H2L2 antibodies, HCAbs (heavy chain only antibodies), and VH domain antibody complexes using transgenic mouse technology licensed from Erasmus MC.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.